Posted on

The effects of essential amino acid supplementation on glucose Concentrations in human

Type of study: randomized double blinded

⁃ Age 50-75 years, inclusive
⁃ Women postmenopausal
⁃ Score ≥ 26 on screening Mini-Mental State Exam
⁃ Fasting plasma triglyceride concentration between 130 and 500 mg/dl

Exclusion Criteria
⁃ Diabetic
⁃ Current renal or liver disease
⁃ Bleeding disorders
⁃ Anaemia
⁃ Endocrine disease (with the exception of well-regulated hypothyroidism)
⁃ Self-reported hepatitis or HIV (Subjects with previously diagnosed hepatitis can be included if asymptomatic and have normal liver enzymes)
⁃ Alcohol abuse (CAGE questionnaire; abnormal liver enzyme values)
⁃ Drug abuse (self-reported abuse of drugs, e.g., amphetamines, cocaine, opioids, marijuana)

Supplements:

   The capsule supplied by (name of the supplier): Ajinomoto company 

   Amino Acid Supplementation: 

If, after prospective participants provided written informed consent, they were found at the screening visit to satisfy the inclusion criteria and not meet any of the exclusion criteria, they began ingesting capsules that contained (non-essential) amino acids (alanine, aspartic acid, and serine) for two weeks. One dose (15 capsules) contained 11 g of amino acids, and participants consumed two doses per day. All participants who passed the screening tests ingested these non-essential amino acids for two weeks (this period was referred to as a “run-in period” to establish a new baseline for metabolite concentrations after two weeks of taking capsules every day, and the non-essential amino acids were seen as being placebo capsules by the investigators), after which they were randomised to receive either capsules containing essential amino acids plus arginine, or to continue taking the capsules containing non-essential amino acids (placebo). After randomisation, participants ingested AA-containing capsules for a further eight weeks. For participants randomised to receive capsules containing essential amino acids plus arginine, each dose (15 capsules, 11 g of amino acids) contained: 0.36 g histidine, 0.94 g isoleucine, 3.95 g leucine, 1.88 g lysine, 0.39 g methionine, 0.51 g phenylalanine, 1.05 g threonine, 0.82 g valine, 1.10 g arginine. As this was a randomised, double-blinded, placebo-controlled trial, neither the study participants nor the investigators knew which supplement (EAA+Arg or placebo) each participant was taking whilst they were in the randomised part of the study, and participants were not made aware that they were specifically taking non-essential acid (placebo) capsules during the two-week run-in phase of the study.

OGTT and blood analysis:

After an overnight fast (10–12 h), a basal blood draw was obtained as 0 min, followed by a 75-g glucose cola administration to the participants. Measured directly Fresh not frozen by using (SST serum separator tube) and Measured by using YSI yellow spring analyzer in The Institute for Translational Sciences (ITS) laboratories.

Type of service: Dissertation Services
Type of assignment: Dissertation
Subject: Healthcare & Medicine
Pages/words: 15/4000
Number of Sources: 0
Academic level: Master’s
Paper Format: MLA
Line spacing: Double
Language style: UK English